In a 48-year-old woman with a history of anxiety disorder who presents with insomnia (difficulty falling asleep, early morning awakening, daytime fatigue, and impaired concentration) due to worry about her daughter's cancer treatment, which prescription sleep medication is most appropriate?

Doxepin is the most appropriate treatment for this patient

For a 48-year-old woman with anxiety disorder presenting with both sleep initiation difficulty and early morning awakening, doxepin is the optimal choice among the listed options. This patient's insomnia pattern—difficulty falling asleep AND early morning awakening with inability to return to sleep—requires a medication that addresses both sleep onset and sleep maintenance throughout the night.

Rationale for Doxepin

Doxepin stands out because it improves multiple sleep parameters that match this patient's specific complaints:

• Addresses both sleep onset latency AND wake after sleep onset 1
• Improves total sleep time and sleep efficiency 1
• Low- to moderate-quality evidence supports its efficacy for global and sleep outcomes 1
• The FDA has approved it specifically for sleep maintenance difficulties, which is critical for this patient's early morning awakening problem

The American College of Physicians guideline specifically identifies doxepin as one of only three medications (along with eszopiclone and zolpidem) with evidence for improving sleep outcomes 1. Importantly, doxepin's pharmacologic profile as a histamine H1 antagonist at low doses provides sustained sleep maintenance without the tolerance issues common to benzodiazepine receptor agonists.

Why Not the Other Options?

Zaleplon (option c) is eliminated immediately—it has an ultra-short half-life (1 hour) designed exclusively for sleep initiation, making it useless for early morning awakening 2. This patient needs coverage throughout the night.

Ramelteon (option a) has insufficient evidence. The ACP guideline explicitly states: "Low-quality evidence showed no statistically significant difference between ramelteon and placebo for sleep outcomes in the general population" 1. While it may decrease sleep onset latency in older adults, this patient is 48 and has prominent sleep maintenance issues that ramelteon does not address.

Eszopiclone (option b) is a reasonable alternative and does have evidence for both sleep initiation and maintenance 3, 1. However, given this patient's history of anxiety disorder, there are important considerations:

• Z-hypnotics like eszopiclone carry risks for cognitive and behavioral changes, including driving impairment 3
• The FDA warns of "sleep driving," behavioral abnormalities, and worsening depression 1
• Observational studies suggest associations with dementia, fractures, and major injury 3, 1
• While z-hypnotics are safe in depression/anxiety 2, doxepin lacks abuse potential and may be preferable for long-term safety in a patient with psychiatric comorbidity

Critical Context: This is Adjustment Insomnia

This patient's insomnia is clearly situational—triggered by her daughter's cancer diagnosis 6 weeks ago. This represents adjustment insomnia (short-term, < 3 months), not chronic insomnia disorder. The ACP guideline technically addresses chronic insomnia (≥ 3 months) 1, but the evidence base still applies.

The ideal approach would be cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment 1, 4, but since the question specifically asks for a prescription sleep aid and the patient requests one, pharmacotherapy is appropriate for short-term use (4-5 weeks per FDA approval) 1.

Practical Implementation

• Start doxepin at the lowest effective dose (3-6 mg for sleep maintenance)
• Use for short-term only (< 6 weeks ideally) 2
• Counsel about next-day sedation risk, though this is less pronounced at low doses
• Strongly recommend concurrent CBT-I or digital CBT-I 2, as behavioral therapy provides longer-lasting benefits 1
• Reassess in 2-4 weeks—if her daughter's treatment stabilizes, taper the medication

Common Pitfall to Avoid

Do not prescribe eszopiclone or other z-hypnotics for extended periods in patients with psychiatric comorbidity without careful monitoring. The observational data on serious harms (dementia, falls, fractures) 3, 1 and the FDA warnings about behavioral changes 1 make doxepin's lack of abuse potential particularly valuable in a patient with anxiety disorder who may be vulnerable to dependence.